Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularizati… Read more
Xbrane Biopharma AB (XBRANE) - Net Assets
Latest net assets as of December 2025: Skr560.65 Million SEK
Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has net assets worth Skr560.65 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr671.62 Million) and total liabilities (Skr110.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr560.65 Million |
| % of Total Assets | 83.48% |
| Annual Growth Rate | 96.16% |
| 5-Year Change | 29.86% |
| 10-Year Change | 422.5% |
| Growth Volatility | 2583.29 |
Xbrane Biopharma AB - Net Assets Trend (2012–2025)
This chart illustrates how Xbrane Biopharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xbrane Biopharma AB (2012–2025)
The table below shows the annual net assets of Xbrane Biopharma AB from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr560.65 Million | +168.85% |
| 2024-12-31 | Skr208.54 Million | +21.71% |
| 2023-12-31 | Skr171.34 Million | -59.68% |
| 2022-12-31 | Skr424.89 Million | -1.59% |
| 2021-12-31 | Skr431.74 Million | +67.53% |
| 2020-12-31 | Skr257.71 Million | +39.81% |
| 2019-12-31 | Skr184.32 Million | +121.89% |
| 2018-12-31 | Skr83.07 Million | -6.03% |
| 2017-12-31 | Skr88.41 Million | -17.61% |
| 2016-12-31 | Skr107.30 Million | +125.85% |
| 2015-12-31 | Skr47.51 Million | +654.37% |
| 2014-12-31 | Skr6.30 Million | -27.53% |
| 2013-12-31 | Skr8.69 Million | +9762.77% |
| 2012-12-31 | Skr88.11K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xbrane Biopharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 83005110800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.06 Million | 0.37% |
| Other Comprehensive Income | Skr10.11 Million | 1.80% |
| Other Components | Skr1.39 Billion | 247.23% |
| Total Equity | Skr560.65 Million | 100.00% |
Xbrane Biopharma AB Competitors by Market Cap
The table below lists competitors of Xbrane Biopharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eduspec Holdings Bhd
KLSE:0107
|
$7.64 Million |
|
PepinNini Minerals Limited
PINK:PEIMF
|
$7.64 Million |
|
Berchtesgadener Bergbahn AG
MU:BGB
|
$7.64 Million |
|
Castile Resources Limited
PINK:CLRSF
|
$7.64 Million |
|
WSOL Public Company Limited
BK:WSOL
|
$7.64 Million |
|
Aksara Global Development Tbk PT
JK:GAMA
|
$7.64 Million |
|
Alla Public Company Limited
BK:ALLA
|
$7.63 Million |
|
Mitsib Leasing Public Company Limited
BK:MITSIB
|
$7.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xbrane Biopharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 208,539,000 to 560,652,000, a change of 352,113,000 (168.8%).
- Net income of 127,242,000 contributed positively to equity growth.
- Share repurchases of 240,000,000 reduced equity.
- New share issuances of 240,000,000 increased equity.
- Other comprehensive income decreased equity by 119,999.
- Other factors increased equity by 224,990,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr127.24 Million | +22.7% |
| Share Repurchases | Skr240.00 Million | -42.81% |
| Share Issuances | Skr240.00 Million | +42.81% |
| Other Comprehensive Income | Skr-120.00K | -0.02% |
| Other Changes | Skr224.99 Million | +40.13% |
| Total Change | Skr- | 168.85% |
Book Value vs Market Value Analysis
This analysis compares Xbrane Biopharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 10.74x to 15.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.53 | Skr5.70 | x |
| 2013-12-31 | Skr52.34 | Skr5.70 | x |
| 2014-12-31 | Skr37.94 | Skr5.70 | x |
| 2015-12-31 | Skr286.18 | Skr5.70 | x |
| 2016-12-31 | Skr307.40 | Skr5.70 | x |
| 2017-12-31 | Skr218.90 | Skr5.70 | x |
| 2018-12-31 | Skr179.60 | Skr5.70 | x |
| 2019-12-31 | Skr233.41 | Skr5.70 | x |
| 2020-12-31 | Skr201.62 | Skr5.70 | x |
| 2021-12-31 | Skr259.32 | Skr5.70 | x |
| 2022-12-31 | Skr235.47 | Skr5.70 | x |
| 2023-12-31 | Skr84.58 | Skr5.70 | x |
| 2024-12-31 | Skr21.19 | Skr5.70 | x |
| 2025-12-31 | Skr0.37 | Skr5.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xbrane Biopharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.70%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 83.52%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.20x
- Recent ROE (22.70%) is above the historical average (-123.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -946.62% | -84.15% | 1.51x | 7.46x | Skr-842.85K |
| 2013 | -24.25% | -1111.87% | 0.02x | 1.06x | Skr-2.98 Million |
| 2014 | -40.84% | -1356.35% | 0.03x | 1.06x | Skr-3.20 Million |
| 2015 | -24.93% | -2732.56% | 0.01x | 1.59x | Skr-16.60 Million |
| 2016 | -31.02% | -1336.83% | 0.02x | 1.10x | Skr-44.02 Million |
| 2017 | -50.83% | -216.34% | 0.19x | 1.26x | Skr-53.78 Million |
| 2018 | -15.93% | -11.72% | 0.45x | 3.04x | Skr-21.54 Million |
| 2019 | -90.86% | -27912.33% | 0.00x | 1.84x | Skr-185.91 Million |
| 2020 | -88.00% | -3324.91% | 0.01x | 1.80x | Skr-252.56 Million |
| 2021 | -44.24% | -1656.22% | 0.02x | 1.59x | Skr-234.19 Million |
| 2022 | -40.53% | -298.91% | 0.08x | 1.63x | Skr-214.71 Million |
| 2023 | -226.56% | -162.60% | 0.37x | 3.81x | Skr-405.31 Million |
| 2024 | -127.66% | -133.98% | 0.24x | 4.04x | Skr-287.07 Million |
| 2025 | 22.70% | 83.52% | 0.23x | 1.20x | Skr71.18 Million |
Industry Comparison
This section compares Xbrane Biopharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $106,934,177
- Average return on equity (ROE) among peers: -113.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xbrane Biopharma AB (XBRANE) | Skr560.65 Million | -946.62% | 0.20x | $7.64 Million |
| 2cureX AB (2CUREX) | $43.03 Million | -69.18% | 0.11x | $1.39 Million |
| Abliva AB (ABLI) | $70.72 Million | -135.06% | 0.24x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $25.35 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $4.79 Million |
| Active Biotech AB (ACTI) | $646.03 Million | 0.00% | 0.35x | $3.42 Million |
| Alzinova AB (ALZ) | $59.11 Million | -10.49% | 0.07x | $3.99 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $12.21 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $4.76 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $757.29K |
| Biosergen AS (BIOSGN) | $22.79 Million | -149.37% | 0.48x | $2.84 Million |